Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6

被引：2

作者：

Patel, M. R. ^{[1
,2
]}

Hamilton, E. P. ^{[2
]}

Piha-Paul, S. A. ^{[3
]}

Henry, J. ^{[4
]}

Banerji, U. ^{[6
]}

Al Hallak, M. N. ^{[5
,7
]}

Okada, H. ^{[8
]}

Qian, M. ^{[9
]}

Zhang, X. ^{[10
]}

Said, N. ^{[11
]}

Chatikhine, V. ^{[12
]}

Fontana, E. ^{[13
]}

机构：

[1] Florida Canc Specialists, Drug Dev Unit, Sarasota, FL USA

[2] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA

[4] HealthOne, Sarah Cannon Res Inst, Drug Dev Unit, Denver, CO USA

[5] Inst Canc Res, Drug Dev Unit, London, England

[6] Royal Marsden Hosp, London, England

[7] Karmanos Canc Inst, Dept Oncol, Detroit, MI USA

[8] Daiichi Sankyo Inc, Clin Sci, Basking Ridge, NJ USA

[9] Daiichi Sankyo Inc, Biostat & Data Management, Basking Ridge, NJ USA

[10] Daiichi Sankyo Inc, Quantitat Clin Pharmacol, Basking Ridge, NJ USA

[11] Daiichi Sankyo Inc, Clin Safety & Pharmacovigilance, Basking Ridge, NJ USA

[12] Daiichi Sankyo Inc, Early Clin Dev, Basking Ridge, NJ USA

[13] Sarah Cannon Res Inst SCRI UK, Drug Dev, London, England

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.677

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

610O

引用

页码：S488 / S489

页数：2

共 50 条

[1] First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
Konecny, G. E.
Hendrickson, A. E. Wahner
Winterhoff, B.
Machado, A.
Chander, C.
Davenport, S.
Bilic, S.
Miller, L. L.
Chung, A.
Press, M. F.
Letrent, S.
Slamon, D.
ANNALS OF ONCOLOGY, 2023, 34 : S517 - S517
[2] FIRST-IN-HUMAN PHASE 1 STUDY OF TORL-1-23, A NOVEL CLAUDIN 6 (CLDN6) TARGETED ANTIBODY DRUG CONJUGATE (ADC) IN PATIENTS WITH OVARIAN CANCER
Konecny, Gottfried
Hendrickson, Andrea Wahner
Winterhoff, Boris
Chander, Cinthiya
Bilic, Sanela
Davenport, Simon
Chung, Adrine
Miller, Lei-Lani
Press, Michael
Letrent, Stephen
Slamon, Dennis
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A67 - A67
[3] Phase I, two-part, mutlicenter, first-in-human (FIH) study of TORL-1-23, a novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patients with advanced solid tumors
Konecny, Gottfried
Hendrickson, Andrea Wahner
Winterhoff, Boris
Kung, Adrine
Miller, Lei-Lani
Press, Michael
Qazi, Ibrahim
Scholler, Nathalie
Dokainish, Hatem
Letrent, Stephen
Slamon, Dennis
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A56 - A56
[4] Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.
Konecny, Gottfried E.
Hendrickson, Andrea Elisabeth Wahner
Winterhoff, Boris
Chander, Cinthiya
Bilic, Sanela
Davenport, Simon
Chung, Adrine
Miller, Lei-Lani
Press, Michael F.
Letrent, Stephen P.
Slamon, Dennis J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: A novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors
Konecny, G. E.
Hendrickson, A. E. Wahner
Winterhoff, B.
Adjei, A. A.
Kung, A.
Miller, L-L.
Press, M. F.
Qazi, I.
Scholler, N.
Dokainish, H.
Letrent, S.
Slamon, D.
ANNALS OF ONCOLOGY, 2024, 35 : S551 - S551
[6] Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+solid tumors
Haanen, J. B. A. G.
Mackensen, A.
Schultze-Florey, C.
Alsdorf, W.
Wagner-Drouet, E.
Heudobler, D.
Borchmann, P.
Busse, A.
Mielke, S.
Bins, S.
Ungerechts, G.
Bokemeyer, C.
Klobuch, S.
Kutsch, N.
Mueller, F.
Desuki, A.
Zhong, W.
Preussner, L.
Tuereci, Oe.
Sahin, U.
ANNALS OF ONCOLOGY, 2024, 35 : S489 - S490
[7] Anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC): Updated results from a phase I study
Yu, X.
Zhang, J.
Liu, J. J.
Yang, J.
Yue, J.
Sun, Y.
Pan, Y.
Sun, M. L.
Qin, Y.
Shen, L.
Song, R.
Ruan, J.
Zhou, A.
Mou, Y.
Aghmesheh, M.
Morris, M.
Yu, X.
Zhao, X.
Chen, M.
Tazbirkova, A.
ANNALS OF ONCOLOGY, 2024, 35 : S1456 - S1456
[8] A FIRST-IN-HUMAN TRIAL OF AN INTEGRIN BETA-6 TARGETED ANTIBODY-DRUG CONJUGATE (ADC), SGNB6A, IN PATIENTS WITH ADVANCED SOLID TUMORS: INTERIM RESULTS OF A PHASE 1 STUDY (SGNB6A-001)
Hollebecque, Antoine
Lopez, Juanita
Piha-Paul, Sarina
Dowlati, Afshin
Patnaik, Amita
Galvao, Vladimir
Buckorny, Bruno
Sehgal, Kartik
Kingsley, Edwin
Sanborn, Rachel
Peters, Solange
Sun, Yan
Patilea-Vrana, Gabriela
Nazarenko, Natalya
Calvo, Emiliano
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A763 - A763
[9] First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.
Chandana, Sreenivasa R.
Choudhury, Noura J.
Dowlati, Afshin
Chiang, Anne C.
Garmezy, Benjamin
Kim, Joo-Hang
Byers, Lauren Averett
Ahn, Myung-Ju
Kim, Tae Min
Kim, Young-Chul
Han, Ji-Youn
Bar, Jair
Zha, Jiuhong
Henner, William
Robinson, Randy
Kohlhapp, Fred
Hingorani, Pooja
Papadopoulos, Kyriakos P.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[10] YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study
Zhao, H.
Ma, Y.
Meng, X.
Wu, L.
Fan, Y.
Zheng, Y.
Liu, Z.
Ji, Y.
Lv, D.
Luo, S.
Sommerhalder, D.
Fu, S.
Huang, Y.
Yang, Y.
Fang, W.
Zhao, Y.
Wang, Y.
Chin, S.
Xue, T.
Zhang, L.
ANNALS OF ONCOLOGY, 2024, 35 : S485 - S485

← 1 2 3 4 5 →